Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future
It has been seventy years since a water-soluble version of vitamin E called tocophersolan (also known as TPGS) was produced; it was approved by USFDA in 1998 as an inactive ingredient. Drug formulation developers were initially intrigued by its surfactant qualities, and gradually it made its way int...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/3/722 |
| _version_ | 1797609546169974784 |
|---|---|
| author | Abhishesh Kumar Mehata Aseem Setia Vikas Ankit Kumar Malik Rym Hassani Hamad Ghaleb Dailah Hassan A. Alhazmi Ahmed A. Albarraq Syam Mohan Madaswamy S. Muthu |
| author_facet | Abhishesh Kumar Mehata Aseem Setia Vikas Ankit Kumar Malik Rym Hassani Hamad Ghaleb Dailah Hassan A. Alhazmi Ahmed A. Albarraq Syam Mohan Madaswamy S. Muthu |
| author_sort | Abhishesh Kumar Mehata |
| collection | DOAJ |
| description | It has been seventy years since a water-soluble version of vitamin E called tocophersolan (also known as TPGS) was produced; it was approved by USFDA in 1998 as an inactive ingredient. Drug formulation developers were initially intrigued by its surfactant qualities, and gradually it made its way into the toolkit of pharmaceutical drug delivery. Since then, four drugs with TPGS in their formulation have been approved for sale in the United States and Europe including ibuprofen, tipranavir, amprenavir, and tocophersolan. Improvement and implementation of novel diagnostic and therapeutic techniques for disease are goals of nanomedicine and the succeeding field of nanotheranostics. Specifically, imaging and treating tumors with nanohybrid theranostics shows promising potential. Docetaxel, paclitaxel, and doxorubicin are examples of poorly bioavailable therapeutic agents; hence, much effort is applied for developing TPGS-based nanomedicine, nanotheranostics, and targeted drug delivery systems to increase circulation time and promote the reticular endothelial escape of these drug delivery systems. TPGS has been used in a number of ways for improving drug solubility, bioavailability improvement, and prevention of drug efflux from the targeted cells, which makes it an excellent candidate for therapeutic delivery. Through the downregulation of P-gp expression and modulation of efflux pump activity, TPGS can also mitigate multidrug resistance (MDR). Novel materials such as TPGS-based copolymers are being studied for their potential use in various diseases. In recent clinical trials, TPGS has been utilized in a huge number of Phase I, II, and III studies. Additionally, numerous TPGS-based nanomedicine and nanotheranostic applications are reported in the literature which are in their preclinical stage. However, various randomized or human clinical trials have been underway for TPGS-based drug delivery systems for multiple diseases such as pneumonia, malaria, ocular disease, keratoconus, etc. In this review, we have emphasized in detail the review of the nanotheranostics and targeted drug delivery approaches premised on TPGS. In addition, we have covered various therapeutic systems involving TPGS and its analogs with special references to its patent and clinical trials. |
| first_indexed | 2024-03-11T06:01:51Z |
| format | Article |
| id | doaj.art-19b68b5256e7403e912bd1ee09a90eb3 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T06:01:51Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-19b68b5256e7403e912bd1ee09a90eb32023-11-17T13:13:28ZengMDPI AGPharmaceutics1999-49232023-02-0115372210.3390/pharmaceutics15030722Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and FutureAbhishesh Kumar Mehata0Aseem Setia1Vikas2Ankit Kumar Malik3Rym Hassani4Hamad Ghaleb Dailah5Hassan A. Alhazmi6Ahmed A. Albarraq7Syam Mohan8Madaswamy S. Muthu9Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, IndiaDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, IndiaDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, IndiaDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, IndiaDepartment of Mathematics, University College AlDarb, Jazan University, Jazan 45142, Saudi ArabiaResearch and Scientific Studies Unit, College of Nursing, Jazan University, Jazan 45142, Saudi ArabiaSubstance Abuse and Toxicology Research Centre, Jazan University, Jazan 45142, Saudi ArabiaClinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaSubstance Abuse and Toxicology Research Centre, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, IndiaIt has been seventy years since a water-soluble version of vitamin E called tocophersolan (also known as TPGS) was produced; it was approved by USFDA in 1998 as an inactive ingredient. Drug formulation developers were initially intrigued by its surfactant qualities, and gradually it made its way into the toolkit of pharmaceutical drug delivery. Since then, four drugs with TPGS in their formulation have been approved for sale in the United States and Europe including ibuprofen, tipranavir, amprenavir, and tocophersolan. Improvement and implementation of novel diagnostic and therapeutic techniques for disease are goals of nanomedicine and the succeeding field of nanotheranostics. Specifically, imaging and treating tumors with nanohybrid theranostics shows promising potential. Docetaxel, paclitaxel, and doxorubicin are examples of poorly bioavailable therapeutic agents; hence, much effort is applied for developing TPGS-based nanomedicine, nanotheranostics, and targeted drug delivery systems to increase circulation time and promote the reticular endothelial escape of these drug delivery systems. TPGS has been used in a number of ways for improving drug solubility, bioavailability improvement, and prevention of drug efflux from the targeted cells, which makes it an excellent candidate for therapeutic delivery. Through the downregulation of P-gp expression and modulation of efflux pump activity, TPGS can also mitigate multidrug resistance (MDR). Novel materials such as TPGS-based copolymers are being studied for their potential use in various diseases. In recent clinical trials, TPGS has been utilized in a huge number of Phase I, II, and III studies. Additionally, numerous TPGS-based nanomedicine and nanotheranostic applications are reported in the literature which are in their preclinical stage. However, various randomized or human clinical trials have been underway for TPGS-based drug delivery systems for multiple diseases such as pneumonia, malaria, ocular disease, keratoconus, etc. In this review, we have emphasized in detail the review of the nanotheranostics and targeted drug delivery approaches premised on TPGS. In addition, we have covered various therapeutic systems involving TPGS and its analogs with special references to its patent and clinical trials.https://www.mdpi.com/1999-4923/15/3/722nanomedicineTPGSnanotheranosticsmultidrug resistanceclinical trialspatents |
| spellingShingle | Abhishesh Kumar Mehata Aseem Setia Vikas Ankit Kumar Malik Rym Hassani Hamad Ghaleb Dailah Hassan A. Alhazmi Ahmed A. Albarraq Syam Mohan Madaswamy S. Muthu Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future Pharmaceutics nanomedicine TPGS nanotheranostics multidrug resistance clinical trials patents |
| title | Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future |
| title_full | Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future |
| title_fullStr | Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future |
| title_full_unstemmed | Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future |
| title_short | Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future |
| title_sort | vitamin e tpgs based nanomedicine nanotheranostics and targeted drug delivery past present and future |
| topic | nanomedicine TPGS nanotheranostics multidrug resistance clinical trials patents |
| url | https://www.mdpi.com/1999-4923/15/3/722 |
| work_keys_str_mv | AT abhisheshkumarmehata vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT aseemsetia vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT vikas vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT ankitkumarmalik vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT rymhassani vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT hamadghalebdailah vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT hassanaalhazmi vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT ahmedaalbarraq vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT syammohan vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture AT madaswamysmuthu vitaminetpgsbasednanomedicinenanotheranosticsandtargeteddrugdeliverypastpresentandfuture |